- Home
- IBIO vs PLRX Comparison
IBIO vs PLRX Comparison
Compare IBIO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | PLRX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | 49 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 69.7M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IBIO | PLRX |
|---|---|---|
| Price | $1.21 | $1.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $4.75 | $2.67 |
| AVG Volume (30 Days) | ★ 534.2K | 360.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.71 | 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $1.02 |
| 52 Week High | $3.82 | $1.95 |
Technical Indicators
Market Signals| Indicator | IBIO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 43.14 |
| Support Level | N/A | $1.02 |
| Resistance Level | $1.52 | $1.37 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 22.76 | 9.09 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.